This site is intended for U.S. healthcare professionals.

Visit Pfizer MedicalVisit Pfizer MedicalLoading

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient ProfilesPatient
ProfilesIdentifying PatientsUnmet NeedsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
HYMPAVZI inhibits tissue factor pathway inhibitor (TFPI)1Watch HYMPAVZI in action HYMPAVZI works within the extrinsic pathway of the coagulation cascade

HYMPAVZI targets TFPI, a natural anticoagulant and primary inhibitor of the
extrinsic coagulation cascade.1-3

 TFPI downregulates the extrinsic pathway

Through the Kunitz 2 (K2) domain, TFPI binds to and inhibits factor Xa (FXa). FXa, along with factor Va (FVa), is a key complex that catalyzes the conversion of prothrombin to thrombin.4,5

 HYMPAVZI inhibits TFPI via the K2 domain

HYMPAVZI targets and inhibits TFPI via the K2 domain, thus helping to prevent TFPI’s inhibition of FXa and leading to thrombin generation and clot formation.1,5

 This anti-TFPI approach is innovative because it helps to achieve hemostasis regardless of factor VIII or factor IX deficiency1,3,6 Bleed protection delivered

In the BASIS study, HYMPAVZI demonstrated reductions in ABR compared with on-demand factor-based treatment and routine factor-based prophylaxis treatment1*

 See efficacy data Loading Bleed protection delivered

In the BASIS study, HYMPAVZI demonstrated reductions in ABR compared with on-demand factor-based treatment and routine factor-based prophylaxis treatment1*

 See efficacy data LoadingABR=annualized bleed rate; FIX=factor IX; FVIII=factor VIII; FXa=factor Xa.92% reduction in treated bleeds on HYMPAVZI compared to on-demand factor-based treatment (3.18 ABR vs 38.00 ABR). 35% reduction in treated bleeds on HYMPAVZI compared to routine factor-based prophylaxis treatment (5.08 ABR vs 7.85 ABR).1References:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2024. 2. Mast AE, et al. J Thromb Haemost. 2022;20(6):1290-1300. 3. Pittman DD, et al. Res Pract Thromb Haemost. 2022;6(2):e12679. 4. Ellsworth P, et al. Hematology Am Soc Hematol Educ Program. 2021;2021(1):219-225. 5. Miyazawa K, et al. Biophys J. 2023;122(1):99-113. 6. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158.About HYMPAVZI Bleed protection

Comparison of ABR of treated bleeds with HYMPAVZI vs on-demand factor-based treatment and routine factor-based prophylaxis treatment1

 See efficacy data Loading

HYMPAVZI is a trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-HYM-USA-0073
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
 
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.